Federal Executive Boards

DGAP-News: asknet Solutions AG: Extraordinary General Meeting approves capital increase to create a solid financial base and enable strategic investments

Friday, October 15, 2021 - 5:04pm

October 15, 2021, Karlsruhe (Germany) - asknet Solutions AG, a leading procurement, e-commerce and EdTech specialist, held today an Extraordinary General Meeting (EGM).

Key Points: 
  • October 15, 2021, Karlsruhe (Germany) - asknet Solutions AG, a leading procurement, e-commerce and EdTech specialist, held today an Extraordinary General Meeting (EGM).
  • During the meeting, the Management Board reaffirmed the company's Three-Pillar Strategy, including a clear roadmap for the years 2021 through 2023.
  • "The execution of our Three-Pillar Strategy, as a clear and material concept to create change and growth for the company, is progressing well.
  • The capital increase approved by the EGM will provide the company with a strong equity base to grow profitably in the coming years.

DGAP-News: CANCOM: New sustainability strategy sets climate neutrality target for 2027

Thursday, October 14, 2021 - 2:29pm

- New sustainability strategy sets targets for social and environmental sustainability.

Key Points: 
  • - New sustainability strategy sets targets for social and environmental sustainability.
  • The key ecological goal is to achieve climate neutrality for the entire CANCOM Group by 2027 at the latest.
  • In addition to climate neutrality, the sustainability strategy also includes investment targets for the training and further education of employees and a donation target for social and charitable commitments.
  • CANCOM's new sustainability website sustainability.cancom.com has been published in parallel with the sustainability strategy.

DGAP-News: STEICO SE: New records for revenues, earnings and profitability

Wednesday, October 13, 2021 - 8:05pm

The high demand for ecological STEICO insulation materials and construction products is continuing and has led to new record-breaking revenues and earnings.

Key Points: 
  • The high demand for ecological STEICO insulation materials and construction products is continuing and has led to new record-breaking revenues and earnings.
  • We are particularly pleased that we were also able to improve profitability even further.
  • EBITDA in Q3 totalled 24.1 million and was thus 35.3% higher than in the previous year (Q3 2020: 17.8 million).
  • The capacity expansions already put in place and upcoming mean that STEICO is excellently equipped to continue its growth.

MilliporeSigma Announces Completion of New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

Tuesday, October 12, 2021 - 2:00pm

This new $110 million, 140,000-square footfacility will more than double the Life Science business sector's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a marketexpected to grow to $10 billion by 2026.

Key Points: 
  • This new $110 million, 140,000-square footfacility will more than double the Life Science business sector's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a marketexpected to grow to $10 billion by 2026.
  • "As a leader in viral vector manufacturing, this increase in capacity and scale is the next step in enabling our customers to bring new curative treatments to market."
  • The new facility leverages cutting-edge suspension technology to enable scalable and cost-effective manufacturing.
  • "We are continuing to invest in solving cell and gene therapy challenges in development and manufacturing, working alongside drug developers to industrialize, scale and accelerate the path to deliver therapies to patients," Heinzel added.

Merck Completes New Viral Vector Contract Development Manufacturing Facility for Gene Therapy

Tuesday, October 12, 2021 - 2:00pm

This new 100 million, 140,000-square foot facility will more than double the company's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a market expected to grow to $10 billion by 2026.

Key Points: 
  • This new 100 million, 140,000-square foot facility will more than double the company's existing capacity to support large-scale commercial and industrial manufacturing for viral gene therapy, in a market expected to grow to $10 billion by 2026.
  • "As a leader in viral vector manufacturing, this increase in capacity and scale is the next step in enabling our customers to bring new curative treatments to market."
  • This is the company's second Carlsbad, California-based facility to serve cell and gene therapy customers driven by the industry's rapid adoption of viral vector-based therapies.
  • With nearly 30 years of experience in cell and gene therapy, Merck offers unique CDMO services streamlined as a single, highly experienced provider.

DGAP-News: InVision AG: Annual General Meeting Approves Stock Option Program

Monday, October 11, 2021 - 10:02am

Dsseldorf (Germany), 11 October 2021 - The Executive Board and Supervisory Board of InVision AG (ISIN: DE0005859698) received strong approval from shareholders at the 2021 Annual General Meeting held on Friday, 8 October 2021.

Key Points: 
  • Dsseldorf (Germany), 11 October 2021 - The Executive Board and Supervisory Board of InVision AG (ISIN: DE0005859698) received strong approval from shareholders at the 2021 Annual General Meeting held on Friday, 8 October 2021.
  • A total of 85.07% of the registered share capital was represented at the virtual Annual General Meeting.
  • Furthermore, the granting and issuing of subscription rights under a 2021 stock option program was resolved.
  • "We are very pleased with the approval of our shareholders regarding the realisation of the 2021 stock option program," said Peter Bollenbeck, CEO of InVision AG.

TUI AG: Allocation of phantom shares under TUI AG's Long Term Incentive Plans

Wednesday, October 6, 2021 - 4:38pm

TUI AG (the "Company") announces that phantom shares ("Phantom Shares") were allocated to the members of the Executive Board set out in the table below under TUI AG's Long Term Incentive Plan.

Key Points: 
  • TUI AG (the "Company") announces that phantom shares ("Phantom Shares") were allocated to the members of the Executive Board set out in the table below under TUI AG's Long Term Incentive Plan.
  • Upon expiry of the 4-year performance period, the Supervisory Board will determine whether the conditions have been satisfied and a possible claim to a payment in respect of the Phantom Shares arises.
  • The Phantom Shares were allocated on 1 October 2021 at a base price of EUR 3.62 per share.
  • This share price equals the average XETRA price of TUI AG shares over a period of 20 trading days before the date of allocation.

DGAP-News: Marinomed Biotech AG signs financing agreement with Nice & Green S.A. to advance its scientific and clinical programs

Tuesday, October 5, 2021 - 7:01am

Marinomed Biotech AG signs financing agreement with Nice & Green S.A. to advance its scientific and clinical programs

Key Points: 
  • Marinomed Biotech AG signs financing agreement with Nice & Green S.A. to advance its scientific and clinical programs
    The issuer is solely responsible for the content of this announcement.
  • Marinomed Biotech AG signs financing agreement with Nice & Green S.A. to advance its scientific and clinical programs
    Korneuburg, Austria, 05 October 2021 - Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced on 04 October 2021, that it has secured financing in a total amount of up to 5.4 million via a flexible Convertible Notes Funding Program (CNFP) from the Swiss investment firm Nice & Green S.A.
  • The agreement between Nice & Green S.A. and Marinomed Biotech AG has a longer term mutually beneficial perspective: As part of the agreement, Nice & Green leverages its network to small- and mid-cap investors and commits to organizing investor webinars and non-deal roadshows in key European financial centers.
  • Marinomed Biotech AG (Korneuburg, Austria) (VSE:MARI) is an Austrian science-based biotech company with globally marketed therapeutics.

Florida Cancer Specialists & Research Institute Names Michael Diaz, MD as President & Managing Physician

Friday, October 1, 2021 - 6:03pm

Fort Myers, Fla, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that Michael Diaz, MD will assume the role of President & Managing Physician, effective January 1, 2022.

Key Points: 
  • Fort Myers, Fla, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that Michael Diaz, MD will assume the role of President & Managing Physician, effective January 1, 2022.
  • Dr. Diaz joined FCS in 2011 and provides care at two FCS office locations in St. Petersburg, Florida.
  • About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
    Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida.
  • In the past four years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.

DGAP-News: Drägerwerk AG & Co. KGaA: Notification pursuant to Art. 5 (1) of the Regulation (EU) No 596/2014 and Art. 2 (1) of the Delegated Regulation (EU) 2016/1052

Friday, October 1, 2021 - 2:46pm

2 (1) of the Delegated Regulation (EU) 2016/1052

Key Points: 
  • 2 (1) of the Delegated Regulation (EU) 2016/1052
    The issuer is solely responsible for the content of this announcement.
  • Drgerwerk AG & Co. KGaA ("Drger") will engage in a share buyback.
  • During November 2, 2021 and probably November 17, 2021 Drger intends to buy back approximately 70.000 of its own preferred shares.
  • the shares are not cancelled but remain in the share accounts of the participating employees during the two-year lock-up period.